Skip to main content
SpringerLink
Log in

Tumor-Specific Approach: Oligodendroglioma (IDH1 Mutated, 1p/19q Deleted)

  • Chapter
  • First Online:
Malignant Brain Tumors

  • 1501 Accesses

Abstract

Oligodendroglioma is a subtype of gliomas which tends to have better outcome compared to other malignant gliomas (astrocytomas) of similar grade. Traditionally, these tumors were managed with a combination of surgery, chemotherapy, and radiation. The introduction of molecular genetics has allowed us to further characterize these tumors that will help in predicting tumor prognosis and aid in treatment planning. This chapter aims to review the current state of oligodendroglioma, the clinical/histologic/molecular characterization, and current/future treatment paradigms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-oncology. 2015;17 Suppl 4:iv1–iv62. PubMed PMID: 26511214. Pubmed Central PMCID: 4623240.

    Google Scholar 

  2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. 2007;114(2):97–109. PubMed PMID: 17618441. Pubmed Central PMCID: 1929165.

    Google Scholar 

  3. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985-90. PubMed PMID: 16168780.

    Google Scholar 

  4. Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-oncology. 2012;14 Suppl 4:iv100–8. PubMed PMID: 23095825. Pubmed Central PMCID: 3480248.

    Google Scholar 

  5. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgard G, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308(18):1881–8.

    Article  CAS  PubMed  Google Scholar 

  6. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol. 2003;60(5):443–56.

    Article  PubMed  Google Scholar 

  7. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. World Health Organization Classification of Tumours. Lyon: IARC Press; 2007. p. 312.

    Google Scholar 

  8. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer genetics. 2012;205(12):613–21.

    Article  CAS  PubMed  Google Scholar 

  9. Schomas DA, Laack NN, Rao RD, Meyer FB, Shaw EG, O’Neill BP, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro-oncology. 2009;11(4):437–45. PubMed PMID: 19018039. Pubmed Central PMCID: 2743224.

    Google Scholar 

  10. Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. The oncologist. 2014;19(4):403–13. PubMed PMID: 24664484. Pubmed Central PMCID: 3983820.

    Google Scholar 

  11. White ML, Zhang Y, Kirby P, Ryken TC. Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol. 2005;26(4):784–90.

    PubMed  Google Scholar 

  12. Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clini Oncol: Official J Am Soc Clini Oncol. 2002;20(9):2267–76.

    Article  CAS  Google Scholar 

  13. Vaquero J, Zurita M, Morales C, Coca S. Prognostic significance of tumor-enhancement and angiogenesis in oligodendroglioma. Acta Neurol Scand. 2002;106(1):19–23.

    Article  CAS  PubMed  Google Scholar 

  14. Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg. 1992;76(3):428–34.

    Article  CAS  PubMed  Google Scholar 

  15. Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, et al. Long-term outcome of oligodendrogliomas. Neurology. 2004;62(10):1783–7.

    Article  CAS  PubMed  Google Scholar 

  16. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP. Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol. 1997;34(1):37–59.

    Article  CAS  PubMed  Google Scholar 

  17. Wieshmann UC, Milinis K, Paniker J, Das K, Jenkinson MD, Brodbelt A, et al. The role of the corpus callosum in seizure spread: MRI lesion mapping in oligodendrogliomas. Epilepsy Res. 2015;109:126–33.

    Article  CAS  PubMed  Google Scholar 

  18. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer. 2004;100(12):2622–6.

    Article  PubMed  Google Scholar 

  19. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clini Oncol:Official J Am Soc Clini Oncol. 2002;20(8):2076–84.

    Article  Google Scholar 

  20. El-Hateer H, Souhami L, Roberge D, Maestro RD, Leblanc R, Eldebawy E, et al. Low-grade oligodendroglioma: an indolent but incurable disease? Clini Article J Neurosurg. 2009;111(2):265–71.

    Article  Google Scholar 

  21. Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med:Official Publ Soc Nucl Med. 2007;48(4):519–27.

    Article  CAS  Google Scholar 

  22. Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, et al. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus. 2015;38(3):E2.

    Article  PubMed  Google Scholar 

  23. Chawla S, Oleaga L, Wang S, Krejza J, Wolf RL, Woo JH, et al. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging:Official J Am Soc Neuroimaging. 2010;20(1):3–8.

    Article  Google Scholar 

  24. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta neuropathologica. 2010;120(3):297–304. PubMed PMID: 20644945. Pubmed Central PMCID: 2910894.

    Google Scholar 

  25. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 2001;60(3):248–62.

    Article  CAS  PubMed  Google Scholar 

  26. Pirzkall A, Nelson SJ, McKnight TR, Takahashi MM, Li X, Graves EE, et al. Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys. 2002;53(5):1254–64.

    Article  PubMed  Google Scholar 

  27. Perry A. Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol. 2001;8(4):183–99.

    Article  CAS  PubMed  Google Scholar 

  28. Kros JM, Van Eden CG, Stefanko SZ, Batenburg M, van der Kwast TH. Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer. 1990;66(6):1204–12 PubMed PMID: 2205356.

    Article  CAS  PubMed  Google Scholar 

  29. Takei H, Yogeswaren ST, Wong KK, Mehta V, Chintagumpala M, Dauser RC, et al. Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival. J Neurooncol. 2008;86(2):183–90.

    Article  PubMed  Google Scholar 

  30. Preusser M, Budka H, Rossler K, Hainfellner JA. OLIG2 is a useful immunohistochemical marker in differential diagnosis of clear cell primary CNS neoplasms. Histopathology. 2007;50(3):365–70.

    Article  CAS  PubMed  Google Scholar 

  31. Eigenbrod S, Roeber S, Thon N, Giese A, Krieger A, Grasbon-Frodl E, et al. alpha-Internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status. J Neuropathol Exp Neurol. 2011;70(11):970–8.

    Article  CAS  PubMed  Google Scholar 

  32. Ducray F, Mokhtari K, Criniere E, Idbaih A, Marie Y, Dehais C, et al. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer. 2011;47(5):802–8.

    Article  CAS  PubMed  Google Scholar 

  33. Barresi V, Mondello S, Branca G, Rajan TS, Vitarelli E, Tuccari G. p-CREB expression in human gliomas: potential use in the differential diagnosis between astrocytoma and oligodendroglioma. Hum Pathol. 2015;46(2):231–8.

    Article  CAS  PubMed  Google Scholar 

  34. Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol. 2003;15(3):197–203.

    Article  CAS  PubMed  Google Scholar 

  35. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999;45(4):923–9.

    Article  CAS  PubMed  Google Scholar 

  36. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90(19):1473–9.

    Article  CAS  PubMed  Google Scholar 

  37. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145(5):1175 Pubmed Central PMCID: 1887413.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66(20):9852–61.

    Article  CAS  PubMed  Google Scholar 

  39. Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M, et al. Two types of chromosome 1p losses with opposite significance in gliomas. Annals Neurology. 2005;58(3):483–7.

    Article  CAS  Google Scholar 

  40. Polivka J Jr, Polivka J, Repik T, Rohan V, Hes O, Topolcan O. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. Anticancer Res. 2016;36(1):471–6.

    CAS  PubMed  Google Scholar 

  41. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clini Oncol:Official J Am Soc Clini Oncol. 2009;27(35):5874–80.

    Article  CAS  Google Scholar 

  42. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clini Oncol:Official J Am Soc Clini Oncol. 2013;31(3):344–50.

    Article  Google Scholar 

  43. Intergroup Radiation Therapy Oncology Group T, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clini Oncol:Official J Am Soc Clin Oncol. 2006;24(18):2707–14.

    Article  Google Scholar 

  44. Wang XW, Ciccarino P, Rossetto M, Boisselier B, Marie Y, Desestret V, et al. IDH mutations: genotype-phenotype correlation and prognostic impact. BioMed Res Int. 2014;2014:540236. PubMed PMID: 24877111. Pubmed Central PMCID: 4022066.

    Google Scholar 

  45. Wesseling P, van den Bent M, Perry A. Oligodendroglioma: pathology, molecular mechanisms and markers. Acta neuropathologica. 2015;129(6):809–27. PubMed PMID: 25943885. Pubmed Central PMCID: 4436696.

    Google Scholar 

  46. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clini Cancer Res:An Official J Am Assoc Cancer Res. 2010;16(5):1597–604.

    Article  Google Scholar 

  47. Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer. 2012;118(2):452–60.

    Article  CAS  PubMed  Google Scholar 

  48. Ahmadi R, Stockhammer F, Becker N, Hohlen K, Misch M, Christians A, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol. 2012;109(1):15–22.

    Article  CAS  PubMed  Google Scholar 

  49. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479–89.

    Article  CAS  PubMed  Google Scholar 

  50. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126(3):443–51.

    Article  CAS  PubMed  Google Scholar 

  51. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012;3(10):1194–203 PubMed PMID: 23104868. Pubmed Central PMCID: 3717947.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Brandner S, von Deimling A. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathol Appl Neurobiol. 2015;41(6):694–720.

    Article  CAS  PubMed  Google Scholar 

  53. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013;126(2):267–76.

    Article  CAS  PubMed  Google Scholar 

  54. Labussiere M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. British journal of cancer. 2014;111(10):2024-32. PubMed PMID: 25314060. Pubmed Central PMCID: 4229642.

    Google Scholar 

  55. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013;126(6):907–15.

    Article  CAS  PubMed  Google Scholar 

  56. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333(6048):1453–5. PubMed PMID: 21817013. Pubmed Central PMCID: 3170506.

    Google Scholar 

  57. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3(7):709–22. PubMed PMID: 22869205. Pubmed Central PMCID: 3443254.

    Google Scholar 

  58. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226(1):7–16. PubMed PMID: 22072542. Pubmed Central PMCID: 3246739.

    Google Scholar 

  59. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Eng J Med. 2005;352(10):997–1003.

    Article  CAS  Google Scholar 

  60. Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-oncology. 2013;15(4):469–79. PubMed PMID: 23408861. Pubmed Central PMCID: 3607260.

    Google Scholar 

  61. Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 2013;81(17):1515–22.

    Article  CAS  PubMed  Google Scholar 

  62. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clini Oncol:Official J Am Soc Clini Oncol. 2013;31(3):337–43. PubMed PMID: 23071247. Pubmed Central PMCID: 3732012.

    Google Scholar 

  63. Sarmiento JM, Venteicher AS, Patil CG. Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas. Cochrane Database Syst Rev. 2015;6:CD009229. PubMed PMID: 26118544. Pubmed Central PMCID: 4506130.

    Google Scholar 

  64. Reijneveld JC, Sitskoorn MM, Klein M, Nuyen J, Taphoorn MJ. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology. 2001;56(5):618–23.

    Article  CAS  PubMed  Google Scholar 

  65. van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998 May;64(5):581–7. PubMed PMID: 9598670. Pubmed Central PMCID: 2170094.

    Google Scholar 

  66. Afra D, Osztie E, Sipos L, Vitanovics D. Preoperative history and postoperative survival of supratentorial low-grade astrocytomas. Br J Neurosurg. 1999;13(3):299–305.

    Article  CAS  PubMed  Google Scholar 

  67. Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Annals of neurology. 2003;53(4):524–8.

    Article  PubMed  Google Scholar 

  68. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998;42(5):1044–55; discussion 55-6. PubMed PMID: 9588549.

    Google Scholar 

  69. Claus EB, Horlacher A, Hsu L, Schwartz RB, Dello-Iacono D, Talos F, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005;103(6):1227–33.

    Article  PubMed  Google Scholar 

  70. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clini Oncol:Official J Am Soc Clin Oncol. 2008;26(8):1338–45.

    Article  Google Scholar 

  71. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549–56.

    Article  CAS  PubMed  Google Scholar 

  72. Nicolato A, Gerosa MA, Fina P, Iuzzolino P, Giorgiutti F, Bricolo A. Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. Surg Neurol. 1995;44(3):208–21; discussion 21-3. PubMed PMID: 8545771.

    Google Scholar 

  73. Englot DJ, Han SJ, Berger MS, Barbaro NM, Chang EF. Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery. 2012;70(4):921–8; discussion 8. PubMed PMID: 21997540.

    Google Scholar 

  74. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol. 2007;14(4):391–8.

    Article  CAS  PubMed  Google Scholar 

  75. Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E. Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas. Zentralblatt fur Neurochirurgie. 2006;67(4):204-9. PubMed PMID: 17106834.

    Google Scholar 

  76. Stockhammer F, Misch M, Helms HJ, Lengler U, Prall F, von Deimling A, et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. 2012;21(3):194–7.

    Article  PubMed  Google Scholar 

  77. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120(6):719–29.

    Article  PubMed  Google Scholar 

  78. Juratli TA, Cahill DP, McCutcheon IE. Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations. Expert Rev Anticancer Ther. 2015;15(6):603–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Surma-aho O, Niemela M, Vilkki J, Kouri M, Brander A, Salonen O, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology. 2001;56(10):1285–90.

    Article  CAS  PubMed  Google Scholar 

  80. Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810–8.

    Article  PubMed  Google Scholar 

  81. Roberge D, Souhami L, Olivier A, Leblanc R, Podgorsak E. Hypofractionated stereotactic radiotherapy for low grade glioma at McGill University: long-term follow-up. Technol Cancer Res Treat. 2006;5(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  82. Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J. Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. Int J Radiat Oncol Biol Phys. 2005;62(3):797–802.

    Article  PubMed  Google Scholar 

  83. Lee DH, Kim EY, Park S, Phi JH, Kim SK, Cho BK, et al. Reclosure of surgically induced spinal open neural tube defects by the intraamniotic injection of human embryonic stem cells in chick embryos 24 hours after lesion induction. J Neurosurg. 2006;105(2 Suppl):127–33.

    PubMed  Google Scholar 

  84. Heppner PA, Sheehan JP, Steiner LE. Gamma knife surgery for low-grade gliomas. Neurosurgery. 2005;57(6):1132–9; discussion. PubMed PMID: 16331161.

    Google Scholar 

  85. Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997;37(2):393–8.

    Article  CAS  PubMed  Google Scholar 

  86. Kano H, Niranjan A, Khan A, Flickinger JC, Kondziolka D, Lieberman F, et al. Does radiosurgery have a role in the management of oligodendrogliomas? J Neurosurg. 2009;110(3):564–71.

    Article  PubMed  Google Scholar 

  87. Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE. Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol. 2008;86(3):321–7.

    Article  PubMed  Google Scholar 

  88. Taphoorn MJ, Schiphorst AK, Snoek FJ, Lindeboom J, Wolbers JG, Karim AB, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Annals Neurol. 1994;36(1):48–54.

    Article  CAS  Google Scholar 

  89. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54(7):1442–8.

    Article  CAS  PubMed  Google Scholar 

  90. Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109(5):835–41. PubMed PMID: 18976072. Pubmed Central PMCID: 3833272.

    Google Scholar 

  91. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clini Oncol:Official J Am Soc Clini Oncol. 2014 Mar 10;32(8):783-90. PubMed PMID: 24516018. Pubmed Central PMCID: 3940537.

    Google Scholar 

  92. Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clini Oncol:Official J Am Soc Clini Oncol. 2012;30(25):3065–70. PubMed PMID: 22851558. Pubmed Central PMCID: 3732006.

    Google Scholar 

  93. al. JCBe. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. ASCO Annual Meeting; Chicago, Illinois2014.

    Google Scholar 

  94. Kouwenhoven MC, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006;42(15):2499–503.

    Article  CAS  PubMed  Google Scholar 

  95. Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, Marie Y, et al. Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Annals Neurology. 2005;58(2):322–6.

    Article  CAS  Google Scholar 

  96. Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M, et al. Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol. 2008;88(3):293–8.

    Article  PubMed  Google Scholar 

  97. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560–6.

    Article  CAS  PubMed  Google Scholar 

  98. Everhard S, Kaloshi G, Criniere E, Benouaich-Amiel A, Lejeune J, Marie Y, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Annals Neurology. 2006;60(6):740–3.

    Article  CAS  Google Scholar 

  99. Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, et al. Quality of life in low-grade glioma patients receiving temozolomide. Neuro-oncology. 2009;11(1):59–68. PubMed PMID: 18713953. Pubmed Central PMCID: 2718960.

    Google Scholar 

  100. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68(21):1831–6.

    Article  CAS  PubMed  Google Scholar 

  101. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clini Cancer Res:An Official J Am Assoc Cancer Res. 2009;15(1):330–7.

    Article  CAS  Google Scholar 

  102. Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol. 2007;82(3):281–8.

    Article  CAS  PubMed  Google Scholar 

  103. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clini Oncol:Official J Am Soc Clinical Oncol. 2004;22(15):3133–8.

    Article  CAS  Google Scholar 

  104. Fisher BJ, Lui J, Macdonald DR, Lesser GJ, Coons S, Brachman D, et al. A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424. 2013.

    Google Scholar 

  105. Baumert BG, Mason WP, Ryan G, Bromberg JE, Bent MJVD, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: a randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). 2013.

    Google Scholar 

  106. Lassman AB. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? CNS Oncol. 2015;4(5):341–6.

    Article  CAS  PubMed  Google Scholar 

  107. Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, et al. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro-oncology. 2012;14(6):761–7. PubMed PMID: 22661585. Pubmed Central PMCID: 3367843.

    Google Scholar 

  108. Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenase mutations in gliomas. Neuro-oncology. 2016 ;18(1):16–26. PubMed PMID: 26188014. Pubmed Central PMCID: 4677412.

    Google Scholar 

  109. Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio, II, et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 2012;26(18):2038–49. PubMed PMID: 22925884. Pubmed Central PMCID: 3444730.

    Google Scholar 

  110. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO reports. 2011;12(5):463–9. PubMed PMID: 21460794. Pubmed Central PMCID: 3090014.

    Google Scholar 

  111. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149–53. PubMed PMID: 19246647. Pubmed Central PMCID: 2671348.

    Google Scholar 

  112. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clinical Oncol:Official J Am Soc Clini Oncol. 2011;29(34):4482-90. PubMed PMID: 22025148. Pubmed Central PMCID: 3236649.

    Google Scholar 

  113. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010;465(7300):966. PubMed PMID: 20559394. Pubmed Central PMCID: 3766976.

    Google Scholar 

  114. Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, et al. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proc Nat Acad Sci United States of Am. 2014;111(39):14217–22. PubMed PMID: 25225364. Pubmed Central PMCID: 4191757.

    Google Scholar 

  115. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010;70(22):8981–7. PubMed PMID: 21045145. Pubmed Central PMCID: 3058858.

    Google Scholar 

  116. Popovici-Muller J, Saunders JO, Salituro FG, Travins JM, Yan S, Zhao F, et al. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in Vivo. ACS Med Chem Lett. 2012;3(10):850–5. PubMed PMID: 24900389. Pubmed Central PMCID: 4025665.

    Google Scholar 

  117. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132):622–6.

    Article  CAS  PubMed  Google Scholar 

  118. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324–7.

    Article  CAS  PubMed  Google Scholar 

  119. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nature Med. 2012;18(4):624–9. PubMed PMID: 22281806. Pubmed Central PMCID: 3615719.

    Google Scholar 

  120. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 2012;4(116):116ra5. PubMed PMID: 22238333. Pubmed Central PMCID: 3772177.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 9500 Euclid Ave./T-28, Cleveland, OH, 44195, USA

    Charles Marc Leyrer & Erin Murphy

  2. Mail Code S73 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Manmeet Ahluwalia

Authors
  1. Charles Marc Leyrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erin Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manmeet Ahluwalia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles Marc Leyrer .

Editor information

Editors and Affiliations

  1. Neurosurgical Oncology, Yale University School of Medicine Neurosurgical Oncology, New Haven, Connecticut, USA

    Jennifer Moliterno Gunel

  2. Yale University School of Medicine, New Haven, Connecticut, USA

    Joseph M Piepmeier

  3. Yale School of Medicine, New Haven, Connecticut, USA

    Joachim M. Baehring

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Leyrer, C.M., Murphy, E., Ahluwalia, M. (2017). Tumor-Specific Approach: Oligodendroglioma (IDH1 Mutated, 1p/19q Deleted). In: Moliterno Gunel, J., Piepmeier, J., Baehring, J. (eds) Malignant Brain Tumors . Springer, Cham. https://doi.org/10.1007/978-3-319-49864-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-49864-5_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-49863-8

  • Online ISBN: 978-3-319-49864-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation